NASDAQ:NARI

Inari Medical (NARI) Stock Price, News & Analysis

$41.99
+0.39 (+0.94%)
(As of 05/2/2024 ET)
Today's Range
$41.69
$42.99
50-Day Range
$37.11
$58.27
52-Week Range
$36.73
$71.85
Volume
1.51 million shs
Average Volume
1.18 million shs
Market Capitalization
$2.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.71

Inari Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
54.4% Upside
$65.71 Price Target
Short Interest
Healthy
7.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Inari Medical in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$1.95 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.25) to $0.37 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.56 out of 5 stars

Medical Sector

500th out of 924 stocks

Surgical & Medical Instruments Industry

58th out of 96 stocks

NARI stock logo

About Inari Medical Stock (NASDAQ:NARI)

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

NARI Stock Price History

NARI Stock News Headlines

Biden out June 13; Kamala won’t replace him?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Biden out June 13; Kamala won’t replace him?
On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.
Q1 2024 Inari Medical Inc Earnings Call
Inari Medical earnings: here's what to expect
Inari Medical (NARI) Scheduled to Post Earnings on Tuesday
Inari Medical CFO sells shares worth $245,760
See More Headlines
Receive NARI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
5/02/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NARI
Fax
N/A
Employees
1,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.71
High Stock Price Target
$84.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+54.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-1,640,000.00
Pretax Margin
0.86%

Debt

Sales & Book Value

Annual Sales
$493.63 million
Cash Flow
$0.10 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
51,817,000
Market Cap
$2.47 billion
Optionable
Optionable
Beta
0.93
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives


NARI Stock Analysis - Frequently Asked Questions

Should I buy or sell Inari Medical stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings
or view top-rated stocks.

What is Inari Medical's stock price target for 2024?

7 equities research analysts have issued 1 year target prices for Inari Medical's shares. Their NARI share price targets range from $50.00 to $84.00. On average, they anticipate the company's stock price to reach $65.71 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts price targets for NARI
or view top-rated stocks among Wall Street analysts.

How have NARI shares performed in 2024?

Inari Medical's stock was trading at $64.92 at the beginning of the year. Since then, NARI stock has decreased by 34.4% and is now trading at $42.56.
View the best growth stocks for 2024 here
.

When is Inari Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our NARI earnings forecast
.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.09. The business had revenue of $132.10 million for the quarter, compared to analysts' expectations of $131.82 million. Inari Medical had a negative trailing twelve-month return on equity of 1.64% and a negative net margin of 4.54%. The firm's revenue was up 22.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.11) EPS.

What guidance has Inari Medical issued on next quarter's earnings?

Inari Medical updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $592.5 million-$602.5 million, compared to the consensus revenue estimate of $588.4 million.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an IPO on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (0.53%), New York State Teachers Retirement System (0.10%), State of Alaska Department of Revenue (0.05%), Louisiana State Employees Retirement System (0.04%), Mirae Asset Global Investments Co. Ltd. (0.04%) and Yousif Capital Management LLC (0.04%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends
.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NARI) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners